Skip to content
Educational information only. Not medical advice. We sell nothing and take no affiliate money.
By /
Peptide drug (FDA approved)Human trialsFDA approved

Desmopressin

Desmopressin acetate

Last reviewed October 27, 2026 · 17 sources · Written for general readers · Compare with another compound →

The bottom line

Desmopressin is an FDA approved drug that tells the kidneys to hold on to water, and it also helps blood clot in some bleeding disorders.[1] It reliably cuts bedwetting and night urination while it is taken, but benefits are modest and often fade after stopping.[2][3] Its biggest danger is hyponatremia, a drop in blood sodium that can cause seizures, coma or death, which is why its labels carry warnings and call for sodium checks and fluid limits.[1][3]

Where the evidence stands

What it is

Desmopressin is a lab made version of vasopressin, also called antidiuretic hormone, the pituitary hormone that helps the kidneys save water. Two changes to its structure make it a separate drug from vasopressin itself.[4][5]

Desmopressin was first approved in the United States in 1978, as DDAVP.[12]

DDAVP tablets are approved for central diabetes insipidus (too little of the body's own water hormone, causing heavy urination and thirst), for short term heavy urination after head injury or pituitary surgery, and for bedwetting in children 6 and older.[4]

DDAVP injection is approved for central diabetes insipidus and to control bleeding in some people with hemophilia A or mild to moderate type 1 von Willebrand disease.[1]

Noctiva, a nasal spray approved in 2017, and Nocdurna, a tablet that dissolves under the tongue approved in 2018, were for adults who wake at night to urinate because they make too much urine at night. Both are now listed as discontinued, as are DDAVP nasal spray products.[13][14][12]

Name
Desmopressin (Desmopressin acetate)
Other names
DDAVP, Noctiva, Nocdurna, dDAVP
Type
Peptide drug (FDA approved)
CAS number
16679-58-6
Formula
C46H64N14O12S2
Molecular weight
About 1069 g/mol

What it does in the body

Desmopressin is a lab made version of vasopressin, also called antidiuretic hormone, which the pituitary releases to help the kidneys save water.[4][5] Its main action is switching on V2 receptors, which makes the kidneys pull water back into the body, and it also raises the level of a clotting protein in the blood.[1] Compared with natural vasopressin, its changes make it last longer and squeeze blood vessels much less.[1]

This is the biology, area by area. A change measured in the body, like a higher blood level, does not always mean a person feels a benefit. The claims check below covers that.

Kidneys and urine

Well established

By switching on V2 receptors in the kidney, it makes the kidney reabsorb more water, so less and more concentrated urine is made.[1] In two 12 week trials in adults 50 and older, nightly bathroom trips fell by about 1.5 versus 1.1 to 1.2 on placebo.[3] Half of a dose given into a vein is cleared in about 2.8 hours, and this stretches to about 8.7 hours in severe kidney disease. About half of it leaves the body unchanged in urine.[1]

Blood sodium and water balance

Measured in people

Because the body holds on to water, drinking too much can dilute blood sodium. In the Noctiva trials, mildly low sodium occurred in about 9% to 12% of people on the drug versus 5% on placebo, and all five people on the higher strength whose sodium fell to severely low levels were 65 or older.[3] Severe drops can cause seizures, coma, breathing failure or death.[1]

Blood clotting

Well established

It raises factor VIII, a clotting protein, and the label tells doctors to also track von Willebrand factor, a partner protein. Factor VIII activity rises by several hundred percent, starting within 30 minutes and peaking at about 1.5 to 2 hours, and the clotting effect lasts about 8 to 12 hours.[1] Repeat doses given closer than about two days apart work less well.[1]

Heart and blood vessels

Well established

Its blood vessel squeezing effect is much weaker than natural vasopressin's.[1] Even so, the injection can cause low blood pressure with a faster heartbeat, or high blood pressure, and blood clots in vessels have been reported.[1]

Bleeding in the brain

Measured in people

In a small trial of 54 people with a brain bleed while taking antiplatelet drugs such as aspirin, the bleed grew in 15% given desmopressin versus 22% on placebo, and death or severe disability at 90 days was 22% versus 37%. The trial was only meant to test whether a larger study was possible, so these differences are not proof.[6]

Brain and memory

Measured in people

Small trials give mixed results. A 15 day nasal spray course did not change memory in 40 healthy students, but short term memory scores were better during desmopressin weeks in a crossover trial of 40 children who wet the bed.[7][8]

How it works

Desmopressin works mainly by switching on the V2 receptor in the kidneys.[1]

  • This makes the kidneys pull more water back into the body, so less urine is made.[1]
  • In people with hemophilia A and type 1 von Willebrand disease, it raises blood levels of factor VIII, a clotting protein.[1]
  • Because the body holds on to water, drinking too much while on the drug can dilute blood sodium to dangerous levels.[4]

These actions are well established and described on the FDA labels.

What the research shows

We keep animal and human evidence apart. A result in animals is a reason to study something in people, not proof that it works in people.

Animal and lab studies

Not the main evidence

  • Desmopressin has been used in people since 1978, and its FDA labels rest on human data, so animal studies add little for readers.[12][1]

Limit: The important questions about desmopressin have been studied in people.

Human studies

Well studied in people, with low sodium as the key concern

  • Bedwetting: a 2025 Cochrane review of 95 studies with 8,473 children found about 1.8 fewer wet nights per week than placebo while taking it, and more children reached 14 dry nights in a row. The certainty of the evidence was low to moderate.[2]
  • Compared with bedwetting alarms, desmopressin worked about as well during treatment, but alarms may leave more children dry after treatment ends.[2]
  • Night urination: two 12 week placebo controlled Noctiva trials enrolled 612 and 433 adults aged 50 and older. Nighttime bathroom trips fell by about 1.4 to 1.5 per night versus 1.1 to 1.2 on placebo, and 35% to 49% cut their trips at least in half versus 27% to 29% on placebo.[3]
  • In those trials, mildly low blood sodium was more common than on placebo, about 9% to 12% versus 5%. All five people on the higher strength whose sodium fell to severely low levels were 65 or older, as was one person on placebo.[3]
  • The most common side effects in those trials were nasal discomfort, stuffy nose, sneezing and nosebleeds, plus higher blood pressure and back pain in a few percent.[3]
  • In bedwetting trials with the tablets, headache was the only drug related side effect seen in at least 3% of children, 4% versus 3% on placebo.[4]
  • Surgery: across 65 trials with 3,874 people, desmopressin did not change how many people needed transfusions. Deaths and blood clots were not clearly different from placebo.[9]
  • Brain bleeds: in the DASH trial, 54 adults with a bleed in the brain while on antiplatelet drugs got desmopressin or placebo. Bleed growth was 15% versus 22%, serious side effects 44% versus 48%, and pneumonia 4% versus 22%. All 54 were followed to the end.[6]
  • Memory: in 40 healthy students, a 15 day nasal spray course did not change memory scores versus placebo. In a crossover trial of 40 children with bedwetting, short term memory scores were better during desmopressin weeks.[7][8]

Limit: Benefits for bedwetting and night urination are real but modest and often fade after stopping, and they must be weighed against the risk of low sodium, which rises with age.[3][2]

Claims check

The most common claims about this compound, and what studies actually found. Verdicts rate the evidence, not whether you should use it.

Stops bedwetting

Shown in people

A 2025 Cochrane review of 95 studies with 8,473 children found desmopressin cut wet nights by about 1.8 per week versus placebo during treatment, and more children reached 14 dry nights in a row. The evidence was of low to moderate certainty, and bedwetting alarms may leave more children dry after treatment ends.[2]

Cuts nighttime bathroom trips in adults

Shown in people

In two 12 week placebo controlled Noctiva trials with 612 and 433 adults aged 50 and older, nightly bathroom trips fell by about 1.5 versus 1.1 to 1.2 on placebo.[3] The benefit was real but modest, and low sodium was more common than on placebo.[3]

Treats diabetes insipidus

Shown in people

FDA approves DDAVP tablets and injection for central diabetes insipidus, where the body lacks its own water hormone, based on desmopressin's proven effect of cutting urine output.[4][1]

Controls bleeding in hemophilia A and von Willebrand disease

Shown in people

The injection is FDA approved to control bleeding in some people with hemophilia A or mild to moderate type 1 von Willebrand disease, because it raises the clotting protein factor VIII by several hundred percent for about 8 to 12 hours.[1]

Reduces bleeding during surgery

Mixed results

A Cochrane review of 65 trials with 3,874 people found desmopressin made little or no difference to how many people needed a blood transfusion. In heart surgery it cut the amount of blood transfused only slightly, which the authors judged unlikely to matter, though people with poorly working platelets may benefit more, based on low quality evidence.[9]

Limits brain bleeds in people on aspirin type drugs

Mixed results

In a 54 person placebo controlled trial, fewer bleeds grew (15% versus 22%) and fewer people died or were severely disabled at 90 days (22% versus 37%) with desmopressin, but the trial was designed only to test feasibility and the authors called for a larger trial.[6]

Boosts memory and focus

Mixed results

A double blind study of 40 healthy students using a nasal spray for 15 days found no memory change, and a 1982 study found no benefit in healthy people or those with memory problems.[7][10] Two small placebo controlled trials did report better memory scores, in 40 children with bedwetting and in 50 patients having electroconvulsive therapy.[8][11]

Known risks and side effects

  • Dangerously low sodium. Desmopressin can cause hyponatremia severe enough to cause seizures, coma, breathing failure or death. The injection label carries a boxed warning about this and calls for sodium checks before and after starting.[1]
  • Higher risk with age. In the Noctiva trials, mildly low sodium occurred in about 12% versus 5% on placebo, and every severe case was in someone 65 or older. Its label required sodium checks.[3]
  • Nasal spray not for bedwetting. DDAVP nasal spray is not meant for bedwetting because it carries a higher risk of low sodium and seizures than the tablets. Children should limit evening drinks while taking it.[15][2]
  • Blood pressure, clots and interactions. The injection can cause low or high blood pressure, a fast heartbeat and, rarely, blood clots.[1] Risk of low sodium rises with heavy drinking of fluids, kidney or heart problems, and some medicines such as certain antidepressants, NSAID pain relievers and seizure drugs.[4]
  • Banned in sport. World Anti Doping Agency rules list desmopressin under diuretics and masking agents, banned at all times, on both the 2026 list and the 2027 list.[16][17]

Regulatory status

Today: Desmopressin is FDA approved, and DDAVP tablets and injection are listed on DailyMed.[4][1] Noctiva, Nocdurna and DDAVP nasal spray products are listed as discontinued.[13][14][12] The 2026 and 2027 World Anti Doping Agency lists both name it as a masking agent banned at all times.[16][17]

  1. FDA approved DDAVP, the first desmopressin product.[12]
  2. FDA approved Noctiva nasal spray for nighttime urination in adults, with a boxed warning for hyponatremia.[13][3]
  3. FDA approved Nocdurna tablets for nighttime urination in adults.[14]
  4. The DDAVP nasal spray label stated that the spray is not for bedwetting because of a higher risk of low sodium and seizures.[15]
  5. The DDAVP injection label was revised, and the current version carries a boxed warning for hyponatremia.[1]
  6. The 2027 World Anti Doping Agency list takes effect and still names desmopressin among masking agents.[17]

Sources

  1. Ferring Pharmaceuticals. DDAVP (desmopressin acetate) injection prescribing information, revised July 2022. DailyMed. DailyMed
  2. Hahn D, Stewart E, Raman G. Desmopressin for nocturnal enuresis in children. Cochrane Database Syst Rev. 2025;7:CD002112. PMID 40728007
  3. NOCTIVA (desmopressin acetate) nasal spray prescribing information, March 2017. NDA 201656. FDA label
  4. Ferring Pharmaceuticals. DDAVP (desmopressin acetate) tablets prescribing information. DailyMed. DailyMed
  5. FDA Global Substance Registration System. Desmopressin, UNII ENR1LLB0FP. FDA GSRS
  6. Desborough MJR, Al-Shahi Salman R, Stanworth SJ, Havard D, Woodhouse LJ, Craig J, Krishnan K, Brennan PM, Dineen RA, Coats TJ, Hepburn T, Bath PM, Sprigg N; DASH trial investigators. Desmopressin for reversal of antiplatelet drugs in stroke due to haemorrhage (DASH): a multi-centre phase II blinded randomised controlled feasibility trial. Lancet Neurol. 2023;22(7):557-567. Lancet Neurol 2023
  7. Guard O, Marchal G, Graule A, Dumas R, et al. Effects of vasopressin and desmopressin on memory. A double-blind study in 40 healthy volunteers. Neuropsychobiology. 1986;15(2):80-3. PMID 3762902
  8. Muller D, Florkowski H, Chavez-Kattau K, Carlsson G, et al. The effect of desmopressin on short-term memory in children with primary nocturnal enuresis. J Urol. 2001;166(6):2432-4. PMID 11696805
  9. Desborough MJ, Oakland K, Brierley C, Bennett S, Doree C, Trivella M, Hopewell S, Stanworth SJ, Estcourt LJ. Desmopressin use for minimising perioperative blood transfusion. Cochrane Database Syst Rev. 2017;7:CD001884. Cochrane CD001884
  10. Jenkins JS, Mather HM, Coughlan AK. Effect of desmopressin on normal and impaired memory. J Neurol Neurosurg Psychiatry. 1982;45(9):830-1. PMID 7131017
  11. Abdollahian E, Sargolzaee MR, Hajzade M, Mohebbi MD, et al. Effects of desmopressin (DDAVP) on memory impairment following electroconvulsive therapy (ECT). Acta Neuropsychiatr. 2004;16(3):130-7. PMID 26984164
  12. US Food and Drug Administration. Drugs@FDA: DDAVP (desmopressin acetate) nasal products, NDA 017922. Drugs@FDA
  13. US Food and Drug Administration. Drugs@FDA: NOCTIVA (desmopressin acetate), NDA 201656. Drugs@FDA
  14. US Food and Drug Administration. Drugs@FDA: NOCDURNA (desmopressin acetate), NDA 022517. Drugs@FDA
  15. Ferring Pharmaceuticals. DDAVP Nasal Spray prescribing information, October 2018. NDA 017922. FDA label
  16. World Anti-Doping Agency. The 2026 Prohibited List. In force 1 January 2026. WADA 2026
  17. World Anti-Doping Agency. The 2027 Prohibited List. In force 1 January 2027. WADA 2027
Medical disclaimer

This page is educational information only. It is not medical advice and does not replace care from a licensed medical provider. Do not use this page to decide whether to take any substance. Talk to a licensed medical provider first.

Found an error or a newer study? We correct pages fast.

Report a correction →
Scroll to Top